Willem Witlox
7PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Feb 28, 2026
Accounting for Genomic Testing Costs in Cost-Effectiveness Evaluations: Challenges and Lessons Learned from the NICE Single Technology Appraisal of Erdafitinib for Treating Unresectable or Metastatic Urothelial Cancer with FGFR3 Alterations After a PD-1 or PD-L1 Inhibitor.Andrea Fernández Coves, Mirre Scholte, Jonathan Emerson
|Feb 16, 2026
Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.Andrea Fernández Coves, Mirre Scholte, Robert Wolff
|Nov 19, 2025
Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective.Isabell Wiethoff, Willem J A Witlox, Silvia M A A Evers
|May 02, 2023
Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Willem Witlox, Sabine Grimm, Jeremy Howick
|Oct 27, 2022
Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Ben Wijnen, Willem Witlox, Robert Wolff
|Dec 10, 2019
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.Willem J A Witlox, Antoinette D I van Asselt, Robert Wolff
Pageof 2
